GlassScriptPhysician profile
Bose Amosun
NPI 1962283622
$2,875.58
in general payments reported to CMS, 2019-2025
27 companies · $1,608 in 2025
The $1,608 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,268 · 2025: $1,608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,875.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $638.46 | 2024-2025 | |
| Janssen Biotech, INC. | $381.69 | 2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $209.43 | 2024-2025 | Entyvio, Trintellix, Eohilia |
| Aimmune Therapeutics, INC. | $169.40 | 2025 | Zenpep, Vowst |
| Pfizer INC. | $168.91 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.27 | 2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $158.29 | 2024 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $107.51 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $100.54 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.43 | 2024-2025 | Xifaxan, Trulance |
| Medtronic, INC. | $84.82 | 2024 | Intellis Adaptivestim |
| Phathom Pharmaceuticals, INC. | $84.45 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $84.27 | 2024 | |
| Corcept Therapeutics | $52.21 | 2024-2025 | Korlym |
| Ipsen Biopharmaceuticals, INC | $49.66 | 2025 | Bylvay, Iqirvo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $44.53 | 2025 | |
| Organon LLC | $39.59 | 2024 | |
| Ironshore Pharmaceuticals INC. | $37.92 | 2024 | |
| Madrigal Pharmaceuticals | $36.53 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $33.87 | 2025 | Suflave, Sutab |
| Celltrion USA INC. | $24.91 | 2025 | Vegzelma |
| Glaxosmithkline, LLC. | $21.92 | 2024 | Arexvy, Trelegy Ellipta |
| Shield Therapeutics INC | $21.24 | 2024 | |
| Seqirus USA INC | $20.95 | 2024 | Flucelvax, Fluad |
| Otsuka America Pharmaceutical, INC. | $18.10 | 2024 | Rexulti |
| Inspire Medical Systems, INC. | $17.66 | 2025 | Inspire |
| Corium, LLC | $14.02 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bose Amosun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.